Bli medlem
Bli medlem

Du är här


Nexstim Oyj: Nexstim Plc ("Nexstim" or the "Company") The decisions of the Board of Directors

Helsinki, 31thMarch 2015 at 15.00 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to
improve rehabilitation for stroke patients through the use of non-invasive
brain stimulation, announces that the Board of Directors of Nexstim Plc. has
today, in the meeting that took place after the Annual General Meeting,
elected the members of the Board Committees as follows:
The chairman of the Audit Committee shall be Juliet Thompson and the members
shall be Juha Vapaavuori and Ekaterina Smirnyagina.

The chairman of the Compensation committee shall be Ken Charhut and the
members shall be Johan Christenson and Olli Riikkala.

For the time being, the following members shall continue in the Nomination
Committee: the chairman shall be Staffan Lindstrand and the members shall be
Sami Tuhkanen and Jos Peeters. The Board Chairman, Olli Riikkala, shall
participate in the Nomination Committee meetings.
The following members of the Board of Directors of Nexstim Plc: Johan
Christenson, Rene Kuijten, Ekaterina Smirnyagina and Juha Vapaavuori and the
members of the Nomination Committee: Staffan Lindstrand, Sami Tuhkanen and
Jos Peeters have announced that they will not be accepting Board fees from
the Company. The above mentioned Board members will be receiving travelling
reimbursements according to the decision of the Annual General Meeting.

Janne Huhtala, Chief Executive Officer

For further information please visit
www.nexstim.comor contact:


+358 (0)40 8615046
Janne Huhtala, Chief Executive Officer

UB Capital Oy
(Certified Adviser)
+358 (0)9 2538 0225

Consilium Strategic Communications

+44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan

About Nexstim Plc

Nexstim, formed in 2000 and based in Finland, is a medical technology company
aiming to improve rehabilitation for stroke patients. Nexstim has pioneered
its technology in brain diagnostics with the Navigated Brain Stimulation
(NBS) system as the first and only FDA-cleared and CE-marked navigated
Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of
the motor and speech cortices. Based on the same technology platform, the
company has developed a device for stroke therapy called Navigated Brain
Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III
study at 12 sites in the US aiming to demonstrate the effectiveness of NBT®
and gain FDA clearance for commercialisation in post-acute stroke therapy in
the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq
First North Sweden. For more information please visit



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.